Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US75062E1064
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00J3YYS92
RFL
Rafael Holdings Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Real Estate Services · THEMEFOLIO: $HLTH
NAME
Rafael Holdings Inc
ISIN
US75062E1064
TICKER
RFL
MIC
XNYS
REUTERS
RFL.N
BLOOMBERG
RFL US
Tue, 03.11.2026       Rafael
US75062E1064

NEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Monday, November 9, 2026 at 3:55 p.m. ET, and host one-on-one meetings with institutional investors....
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investi...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.10.2026       Rafael
US75062E1064

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026....
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.10.2026       Rafael
US75062E1064

NDA supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or  the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The invest...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Rafael and certain of its officers and/or...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.10.2026       Rafael
US75062E1064

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Rafael and certain of its officers and/or di...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.09.2026       Rafael
US75062E1064

Please post to IR news on company website and send to excel distribution list on file. Thank you. Best, Barbara...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Rafael
US75062E1064

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026....
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.06.2026       Rafael
US75062E1064

Topline results are expected to be announced in second half of calendar 2026...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 22.04.2026       Rafael
US75062E1064

License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Rafael
US75062E1064

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026....
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Rafael
US75062E1064

NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025....
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.10.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.08.2025       Rafael
US75062E1064

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15th International Congress...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.06.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatme...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the tr...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.03.2025       Rafael
US75062E1064

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.12.2024       Rafael
US75062E1064

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 07.11.2024       Rafael
US75062E1064

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.08.2024       Rafael
US75062E1064

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Rafael Holdings, Inc. (NYSE: RFL) and Cyclo Therapeutics, Inc. is fair to Rafael shareholders. Halper Sadeh encourages Rafael shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.08.2024       Rafael
US75062E1064

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.06.2024       Rafael
US75062E1064

Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.03.2022       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - March 23, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rafael and certain o...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.03.2022       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - March 14, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rafael and certain o...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.10.2021       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an invest...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.08.2021       Rafael
US75062E1064

New York, New York--(Newsfile Corp. - August 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdings" or the "Company") (NYSE: RFL) stock prior to August 16, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investi...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.06.2021       Rafael
US75062E1064

Philadelphia, Pennsylvania--(Newsfile Corp. - June 28, 2021) - Kaskela Law LLC announces that it is investigating Rafael Holdings, Inc. ("Rafael Holdings") (NYSE: RFL) on behalf of the company's stockholders.On June 21, 2021, Rafael Holdings announced that it had entered into an agreement to acquire Rafael Pharmaceuticals, Inc. ("Pharmaceuticals")...
Read more
Rafael
Technical Analysis Termsheets Terminal
Permalink